Evidence map›Paper›PMID 29204054›Full record

ArticleWorld journal of gastroenterology2017

Nuclear heat shock protein 110 expression is associated with poor prognosis and hyperthermo-chemotherapy resistance in gastric cancer patients with peritoneal metastasis.

Akiharu Kimura, Kyoichi Ogata, Bolag Altan, Takehiko Yokobori, Erito Mochiki, Mitsuhiro Yanai, Norimichi Kogure, Toru Yanoma, Masaki Suzuki, Tuya Bai and 1 more

Open access · hybridAbstract read
In one paragraph

Article in World journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Akiharu Kimuraand Hiroyuki Kuwano, Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan. akimura@gunma-u.ac.jp.
Kyoichi Ogataand Hiroyuki Kuwano, Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan.
Bolag Altanand Hiroyuki Kuwano, Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan.
Takehiko Yokoboriand Hiroyuki Kuwano, Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan.
Erito MochikiDepartment of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama 350-0844, Japan.
Mitsuhiro Yanaiand Hiroyuki Kuwano, Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan.
Norimichi Kogureand Hiroyuki Kuwano, Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan.
Toru Yanomaand Hiroyuki Kuwano, Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan.
Masaki Suzukiand Hiroyuki Kuwano, Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan.
Tuya Baiand Hiroyuki Kuwano, Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan.
Hiroyuki Kuwano
Gunma University · JPSocial Insurance Saitama Chuo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the significance of heat shock protein 110 (HSP110) in gastric cancer (GC) patients with peritoneal metastasis undergoing hyperthermo-chemotherapy.

methodsPrimary GC patients (

resultsHSP110 immnohistochemical staining in 14 GC patients showed that five (35.7%) samples belonged to the low expression group, and nine (64.3%) samples belonged to the high expression group. Progression-free survival was significantly shorter in the HSP110 high-expression group than in the low-expression group (

conclusionThe expression of nuclear HSP110 in GC patients might be a new marker of chemosensitivity and a therapeutic target for patients who are tolerant to existing hyperthermo-chemotherapies.

Indexed as

Drug Resistance, NeoplasmAntineoplastic AgentsBenzhydryl CompoundsCell Line, TumorCisplatinFemaleHSP110 Heat-Shock ProteinsHumansHyperthermia, InducedMaleMiddle AgedPeritoneal NeoplasmsPeritoneumPyrrolidinonesStomach NeoplasmsAntineoplastic AgentsBenzhydryl CompoundsCisplatinHSP110 Heat-Shock ProteinsHSPH1 protein, humanKNK 437PyrrolidinonesDrug resistanceGastric cancerHeat shock protein 110HyperthermiaHyperthermo-chemotherapyPeritoneal metastasis

Identifiers

PMID29204054
PMCPMC5698247
OpenAlexW2767793341

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.